Stand Up To Cancer (SU2C) has announced that its ninth biennial roadblock televised fundraising special will air on Friday, Aug. 15, from Nashville, bringing together country music stars, celebrities, athletes, cancer researchers and survivors for a powerful evening of inspiration and celebration.

This marks the first time the telecast will be broadcast from Nashville, and it will take place at The Pinnacle, a new premier event venue in the heart of Music City. Airing at 7 p.m. CT, the one-hour special continues SU2C’s 17-year mission to fund cancer research and save lives.

With the move to Nashville, SU2C will harness the city’s creative energy and musical heritage to bring a new dimension and excitement to this year’s show. The telecast will feature artists from country and other musical genres coming together in unique collaborations, an artistic reflection of SU2C’s commitment to scientific teamwork where researchers unite to accelerate progress.

Music icon Dolly Parton will appear in the special, with GRAMMY Award-winning artist Sheryl Crowserving as host. Additional performers and celebrity participants will be revealed in the weeks ahead.

Vanderbilt-Ingram Cancer Center is welcoming SU2C to Nashville.

“We are thrilled that Stand Up To Cancer will be bringing this special event to Nashville, and we welcome them to our city,” said Ben Ho Park, MD, PhD, Benjamin F. Byrd Jr. Professor of Oncology, professor of Medicine, and director of Vanderbilt-Ingram. “Our physicians, researchers and patients are familiar with the exceptional work of this organization that funds research to advance cancer treatments, which ultimately saves lives.

“This will be an extraordinary evening featuring some of Nashville’s most talented entertainers, and we hope everyone will join us for the telecast that will showcase not only our great city, but also the amazing research that has emanated from SU2C.”

As a leading academic medical center with deep roots in the region, Vanderbilt-Ingram shares SU2C’s commitment to advancing cancer research and improving patient outcomes.

“The goal of Stand Up To Cancer has always been about working collaboratively to push cancer research forward so we could help patients as quickly as possible,” said Katie Couric, SU2C co-founder. “Nearly two decades later, it’s incredibly gratifying and inspiring to see the impact of this research. Bringing the show to Nashville will infuse new energy and excitement into our mission. There’s still so much work to do and every dollar makes a difference — especially to the families who are counting on novel approaches and therapies as they face the challenges that often accompany a cancer diagnosis.”

The biennial special will be carried across more than 30 participating media platforms, including all four major U.S. broadcast networks, which are generously donating one hour of commercial-free primetime. Viewers will also be able to watch the telecast on-demand across multiple digital and streaming platforms, ensuring broad and flexible access to this one-night-only event.

Telecast viewers will hear from leading SU2C-funded researchers about recent advances and why continued support is vital in the fight against cancer. The program will also feature powerful stories from survivors who benefited from research made possible by donor contributions. From early detection to new treatment approaches, these stories reflect the real-world impact of SU2C-funded research and the hope it brings to patients and families.

Stand Up To Cancer was established in 2008 by a group of women who wanted to galvanize the entertainment community to raise awareness and funding to advance collaborative cancer research and end cancer as a leading cause of death.

Since its inception, SU2C has brought together over 3,100 top researchers from more than 210 leading institutions across 16 countries to collaborate on advancing cancer research.

SU2C-funded research has contributed to the saving of tens of thousands of lives worldwide.

To learn more about the 2025 event, visit https://standuptocancer.org. For more information visit StandUpToCancer.org, Instagram, TikTok, X, Facebook, and YouTube. 

The post Stand Up To Cancer heads to Nashville for ninth roadblock fundraising special uniting country music and cancer research appeared first on VUMC News.

Susan G. Komen has awarded $10.8 million in new research grants that will help propel innovative science and deliver hope to those facing breast cancer. The grant recipients include three researchers from Vanderbilt University Medical Center.

The grants support 25 cutting-edge projects at 17 institutions — marking a powerful commitment to improving outcomes for people living with breast cancer today and in the future.

“We are proud to support these exceptional researchers who are pushing the boundaries of what’s possible in breast cancer science,” said Paula Schneider, president and CEO of Susan G. Komen. “Research saves lives, and now more than ever, we must invest in science that brings hope to patients — especially those facing the most aggressive forms of breast cancer.”

The three VUMC researchers were each awarded Komen Leadership Grants of $400,000. The Komen Leadership Grant Program supports innovative, hypothesis-driven breast cancer research that aligns with Komen’s mission to save lives and improve personalized care and outcomes for all. Open to Komen’s Scientific Advisors and to Komen Scholars, the program funds bold, high-risk/high-reward projects with the potential to significantly advance the field of breast cancer research.

The VUMC recipients are Tuya Pal, MD, Ingram Professor of Cancer Research and professor of Medicine; Ben Ho Park, MD, PhD, Benjamin F. Byrd Jr. Professor of Oncology and professor of Medicine; and Jennifer Pietenpol, PhD, Ingram Professor of Cancer Research and professor of Biochemistry.

Through this research investment, Komen is prioritizing the most pressing challenges facing patients, including metastatic breast cancer, optimal health for all and the need for more precise, personalized treatment strategies to improve care and outcomes for everyone impacted by breast cancer.

“Komen’s commitment to breast cancer research comes at a pivotal time and will drive meaningful advances in our understanding of the disease and care of patients,” said Ann Partridge, MD, MPH, Chief Scientific Advisor for Komen. “By fueling science that is both innovative and inclusive, we’re accelerating progress where patients need it most — while building a foundation for individualized care for all.”

Komen is the largest nonprofit funder of breast cancer research outside the U.S. government, investing nearly $1.1 billion since its inception. Unlike many research institutions, Komen’s work is powered entirely by the generosity of individual donors, corporate partners and community supporters.

“Investing in top scientific talent is one of the most powerful ways we can drive progress,” said Pietenpol, PhD, Chief Scientific Advisor for Komen. “Komen’s commitment, especially to early-career researchers, cultivates a vibrant ecosystem where bold ideas and pioneering research can thrive, accelerating our path toward the cures we urgently seek.”

Pietenpol holds the Brock Family Directorship in Career Development at VUMC. Park is director of the Vanderbilt-Ingram Cancer Center and a member of the Komen Scientific Advisory Board. Pal is a Komen Scholar.

The post Three VUMC researchers receive Komen leadership grants appeared first on VUMC News.

Cancer patients who scored lower on health literacy screening experienced higher all-cause mortality, according to a study published in the journal Cancer.

The study followed Vanderbilt-Ingram Cancer Center patients for a median of 3.1 years who had taken the Brief Health Literacy Screen. Patients who had high health literacy on the screening lived 9.4 months longer compared to those with low health literacy (score of nine or lower). The 9,603 patients in the retrospective cohort study were diagnosed with either prostate, lung, breast, renal, colorectal, brain, head and neck, bladder, pancreatic, liver, sarcoma or gastric cancer.

“Cancer care is extremely complex, and we highlight that health literacy is an important risk factor in terms of survival in one of the largest studies conducted evaluating the impact of health literacy and cancer survival,” said the study’s senior author, Kamran Idrees, MD, MSCI, MMHC, Ingram Professor of Cancer Research, professor of Surgery and chief of the Division of Surgical Oncology and Endocrine Surgery.

He further stated, “Since health literacy is a modifiable risk factor, it provides us an opportunity for real-time identification of patients with low health literacy to personalize care, provide health literacy sensitive resources, tailored instruction and education to improve their cancer care.”

The screening consists of three multiple-choice questions about patients’ comfort levels with understanding medical information and filling out hospital forms. A point system, ranging from one to five, is assessed according to answers to the questions.

Although the study did not seek to discover causal findings, such as direct links between patient mortality and patients’ ability to make informed decisions about treatment scenarios, the investigators surmised the difference in outcomes was likely multifactorial.

The investigators stated they endorsed the routine collection of health literacy information for patients diagnosed with cancer and that they encouraged the adoption of strategies to improve organizational health literacy in facilities that provide cancer care. They noted that not all cancer patients with low health literacy experienced worse outcomes. Observational studies for specific cancer types that assess health literacy are needed to evaluate interventions aimed at improving outcomes, they said.

Other Vanderbilt authors on the study included Kelvin Moses, MD, PhD, Julia Whitman, MS, and Sunil Kripalani, MD, MSc.

The investigators state that to their knowledge the study is the first to assess the association between health literacy and all-cause mortality among different cancer types.

The research received support from a Society of Surgical Oncology Foundation Investigator Award for a grant titled “Health Literacy and Cancer Outcomes.”

The post Lower health literacy increases mortality risk for cancer patients appeared first on VUMC News.

A study published in the journal JAMA Surgery demonstrated the benefits of using fluorescence-guided imaging to assess margins in head and neck cancer. Researchers at Vanderbilt University Medical Center found that leveraging data collected both during surgery (in vivo) and after the tumor’s removal (ex vivo) can help guide surgeons in achieving a negative margin in cancer resection. 

A margin refers to the areas around the tumor being removed. The desirable outcome is to complete surgery with a negative margin, indicating that no cancer was found at the edge of the resection. A positive margin indicates that cancer cells remain in the tissue, which increases the risk of recurrence and reduces the chance of survival. 

To assess those margins, surgeons may use fluorescent agents administered to the patient’s tissue. Systemically infused agents have been shown to differentiate cancerous and healthy tissue with high accuracy. 

“Our research found that the use of fluorescence imaging both internally and externally can improve surgeons’ ability to precisely and safely excise tumors,” said Shravan Gowrishankar, MD, a research fellow in the Department of Otolaryngology-Head and Neck Surgery and the study’s first author. “This research seeks to illuminate methods of leveraging fluorescence imaging to achieve negative margins, particularly for deep resections, which often prove difficult.” 

The researchers defined two classifications of margins: the superficial or mucosal margin refers to the area uninvolved with the tumor but surrounding its surface, while the deep margin refers to the 4 to 5 millimeters of healthy tissue beyond the tumor’s most invasive points, or the depth of normal tissue between the tumor edge and the cut surface of the specimen. 

“Currently, it’s easier to achieve negative mucosal margins than deep margins,” said corresponding author Eben Rosenthal, MD, chair of the Department of Otolaryngology-Head and Neck Surgery and Barry and Amy Baker Professor of Laryngeal, Head and Neck Research. “Deep margins aren’t able to be assessed as easily because surgeons must rely on estimation of the distance from the tumor to guide the resection. 

“We sought to improve methods of achieving negative margins across the board because estimation isn’t good enough where patient safety is concerned.” 

The assessment of deeper margins is further confounded during surgery by tissue retraction and the presence of blood, which can obscure the view of the surgeon. And while autofluorescence — a process by which naturally occurring chemicals in the tissue can absorb light of a particular wavelength and reemit it at a different wavelength — can help surgeons assess mucosal margins, deeper margins are impossible to assess via this process because the light does not penetrate beyond a millimeter. 

To assist in ensuring a negative margin in a deep resection, surgeons can use fluorescence imaging techniques. Mapping tumors after resection can provide data on how close the margins are to the surface of the deep resection, and intraoperative in vivo fluorescence imaging can reveal areas of residual disease in the tumor bed. In combination, the information provided by both methods of fluorescence imaging can guide further examination and sampling to help achieve fuller resection of the deep margin. 

While both methods in combination are critical to achieving better outcomes in surgery, said Gowrishankar, ex vivo imaging devices have certain advantages over in vivo hardware. 

“While the data we get from in vivo imaging is valuable, it’s largely qualitative because of variance in ambient light in the operating room,” said Gowrishankar. “Ex vivo imaging is more precise because we can seal out external light in a controlled environment to measure fluorescence intensity and guide our assessment of deep margins.” 

In ex vivo imaging, fluorescence intensity increases the closer the tumor tissue approaches the cut surface of the tumor specimen, and data from this measurement can be used to create a sort of “heat map” measuring the relative depth of the tumor across the entire specimen. By using this imaging technique, surgeons can more precisely detect the reach of cancer cells in the tissue and perform precise resections. 

“Mucosal margins are easy enough to detect during surgery without fluorescent agents, but those agents are critical in helping us close the gap with deep margins,” said Rosenthal. “Missed deep margins contribute to the majority of positive margins after resection, which in turn contribute to negative health outcomes for patients. Large-scale adoption of these techniques will have a meaningful impact on the health of patients who undergo surgery to remove cancerous tumors.” 

Additional authors from Vanderbilt University Medical Center include: 

• Jennifer Choe, MD, PhD, assistant professor of Medicine in the Division of Hematology Oncology 

• Alexander Langerman, MD, SM, FACS, associate professor of Otolaryngology-Head and Neck Surgery 

• Kyle Mannion, MD, FACS, associate professor of Otolaryngology-Head and Neck Surgery 

• Aviva S. Mattingly, MD, MS, VTOPS/R25 Research Resident 

• Sarah L. Rohde, MD, MMHC, associate professor of Otolaryngology-Head and Neck Surgery and division director of Head and Neck Oncologic Surgery 

• Robert Sinard, MD, FACS, professor of Otolaryngology-Head and Neck Surgery 

• Hidenori Tanaka, MD, PhD, visiting assistant professor of Otolaryngology-Head and Neck Surgery 

• Michael Topf, MD, MSCI, assistant professor of Otolaryngology-Head and Neck Surgery. 

This research was supported by the National Cancer Institute, part of the National Institutes of Health (grants R01CA279249, R01CA239257, R01CA266233 and R01CA238686). 

The post Data from fluorescence imaging can improve outcomes in head and neck cancer surgery: study  appeared first on VUMC News.

One person in 10 over the age of 70 will experience an explosive, clonal growth of abnormal blood cells, called clonal hematopoiesis of indeterminant potential or CHIP, that increases the risk of blood cancer and death from cardiovascular, lung and liver disease. 

The risk of blood cancer differs significantly, however, depending upon whether patients with CHIP also develop cytopenia (low blood cell count). 

An analysis of genetic sequencing data from more than 34,000 people over a 17-year period by researchers at Vanderbilt University Medical Center has found that persistent cytopenia appears to be a critical step in the progression of CHIP to blood cancer. 

For patients with CHIP who developed cytopenia, the risk of progression to blood cancer was 10 times higher than it was for patients without cytopenia — a 1-in-200 chance per year versus 1 in 2,000, the researchers report in the June 2025 issue of the Lancet journal, eClinicalMedicine.  

These findings suggest that checking blood counts regularly may be an effective way to monitor patients with CHIP for their risk of developing blood cancer, and cytopenia-free survival may be a valuable endpoint for clinical trials aimed at preventing blood cancer in these patients.

“This work is the largest longitudinal analysis of its kind and provides a roadmap for identifying high-risk CHIP patients who may benefit from closer monitoring or early intervention,” said the paper’s corresponding author, Alexander Bick, MD, PhD, associate professor of Medicine and director of the Division of Genetic Medicine at VUMC. 

“It also lays the groundwork for more feasible and targeted clinical trials in blood cancer prevention,” he said. 

Bick is internationally known for his research on the genetics of blood disorders. He and his colleagues have advanced the understanding of somatic (non-inherited) mutations in blood stem cells that can trigger a potentially life-threatening clonal growth of abnormal cells known as CHIP.  

Blood cancer (myeloid neoplasm) results from the abnormal growth of myeloid (blood) cells in the bone marrow. The current study compared blood cancer rates in patients with CHIP who did not develop cytopenia, to those with both CHIP and concurrent, clonal cytopenia of undetermined significance. 

Led by the paper’s first authors, James Brogan, MD, MS, a resident physician in the Department of Medicine, and Ashwin Kishtagari, MD, assistant professor of Medicine in the Division of Hematology and Oncology, the study required large numbers. 

The researchers pulled genetic sequencing data from three major population-level cohorts: the National Institutes of Health (NIH) All of Us Research Program, the UK (United Kingdom) Biobank and VUMC’s biobank, BioVU. 

With roughly 350,000 DNA samples collected to date, BioVU is the world’s largest repository of genetic material linked to de-identified electronic health records (EHRs) based at a single academic center.  

Access to whole genome sequences linked to EHRs for more than 107,000 adults enrolled in BioVU between 2006 and 2023 was provided through the Alliance for Genomic Discovery (AGD), a unique endeavor to accelerate the application of large-scale genomics to biomedical science and therapeutic development. 

Launched in 2022 by Nashville Biosciences LLC, a wholly owned VUMC subsidiary, and the global DNA sequencing giant Illumina Inc., AGD now includes eight major pharmaceutical companies that support the development and availability of whole genome sequences for research aimed at identifying disease associations and targets for intervention. 

The report in eClinicalMedicine “is one of the first papers to leverage data from the BioVU/Alliance for Genomic Discovery whole genome sequencing effort,” Bick said. “It also highlights how at VUMC medical trainees are doing cutting-edge research while developing as physicians.” 

Between the three biobanks, the researchers had access to 805,000 whole genome sequences. From this pool, they identified 8,114 individuals with CHIP who did not develop cytopenia and 1,260 who did. These 9,374 cases were matched with 24,749 controls who did not have CHIP. 

The annual blood cancer progression rate for participants with CHIP who did not develop cytopenia was nearly the same as the rate observed in the control population without CHIP (0.06% versus 0.04%), whereas the rate was 10 times higher for those with both CHIP and cytopenia (0.5% per year). 

Approximately 13% of participants with CHIP developed a cytopenia within five years. Men, smokers and older individuals (over 64) were at a higher risk of developing cytopenia, as were those who had two or more mutations or any high-risk mutations associated with CHIP. 

“Given the substantial risk of cytopenia, patients with multiple high-risk features may benefit from regular monitoring for cytopenia progression,” the researchers concluded. The good news is that this five-year window before the development of cytopenia and blood cancer “provides an opportunity for early intervention with potential disease-modifying therapies,” they wrote.  

Treatments for cytopenia range from drugs that stimulate the production of certain blood cell types to bone marrow or stem cell transplants. 

Co-authors from the Bick lab included rheumatology fellow Robert Corty, MD, PhD, Yash Pershad, an MD-PhD student, and Brian Sharber, MS. Other VUMC co-authors included faculty members Brett Heimlich, MD, PhD, Leo Luo, MD, Brent Ferrell Jr., MD, Michael Savona, MD, and Yaomin Xu, PhD. 

This research was supported by NIH grants DP5OD029586, R01AG088657, R01AG083736, and P30CA068485, the Burroughs Wellcome Fund Career Award for Medical Scientists, the Edward P. Evans Foundation, and the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. 

Savona holds the Beverly and George Rawlings Directorship. Bick is supported in part by a Hevolution/AFAR New Investigator Award in Aging Biology and Geroscience Research, and Brogan is supported in part by an American Society of Hematology HONORS Award.

The post Low blood cell counts drive cancer in explosive blood disorder: study appeared first on VUMC News.

An early-stage clinical trial, supported by the Department of Defense, has demonstrated that the targeted cancer drug trametinib shows potential as an interventional therapy to reprogram precancerous gastric lesions, potentially preventing them from becoming malignant, and that it can be administered safely.

The results of the Phase 1 trial involving 15 patients, which were published recently in Gastroenterology, were pleasantly surprising, said James Goldenring, MD, PhD, professor of Surgery and of Cell and Developmental Biology at Vanderbilt University Medical Center.

The primary goal of this trial was to evaluate whether a low-dose, limited duration treatment of two weeks with trametinib would be safe for patients at risk for developing a second cancer after having undergone resection of a Stage 1 gastric cancer. The drug also showed promise that it could be the first therapeutic intervention against precancerous lesions in the stomach.

Endoscopies revealed that trametinib reversed metaplasia, which is an abnormal change of cells into ones that are non-native to the tissue and can progress to dysplasia, an irreversible change in cell development that can lead to cancer. While the 15 patients in the study had no evidence of recurrent cancer, they did have extensive metaplasia when they entered the study.

“I was pleasantly surprised at how much benefit we could see in the endoscopies after one month and one year; it really was pretty remarkable,” said Goldenring, the Paul W. Sanger Professor of Experimental Surgery.

The reversal of the metaplasia could be viewed in endoscopic images and was confirmed with biopsies.

“I think that’s almost more compelling than anything else in this study,” Goldenring said. “I honestly did not expect endoscopies to be that different, but they were.”

However, he noted that follow-up clinical trials with more participants are needed to further validate the drug’s efficacy. The only significant side effect among the participants was one patient with a mild increase in blood pressure after trametinib treatment that returned to normal after the patient stopped taking the drug.

The patients in the study were recruited from Japan, where the clinical trial was led by Sachiyo Nomura, MD, PhD, in collaboration with Goldenring. Trametinib is an inhibitor of the MEK signaling pathway. MEK, an abbreviation for the mitogen-activated extracellular signal-regulated kinase pathway, plays an integral role in the development of stomach cancer.

The study was supported by a $2.5 million Department of Defense Translational Team Science Award, which is also supporting another clinical trial in the United States with similar aims. The U.S. clinical trial will evaluate the effectiveness of pyrvinium, an existing medicine that has been used for the past 70 years to treat pinworms in children, for a new purpose — reversing metaplasia of stomach cells and killing dysplastic precancerous cells. Pyrvinium also blocks the MEK pathway.

While stomach cancer is one of the three leading causes of cancer-related deaths worldwide, its incidence is lower is the U.S. Nevertheless, it does occur more frequently among minority ethnic groups, and incidence has been rising among young women. DOD support for clinical trials reflects the increased incidence of stomach cancer in minority groups, which make up a higher percentage of the U.S. armed services than of the general population. In the U.S., most stomach cancers are diagnosed at late stages when they are more difficult to treat.

Goldenring said he hopes the MEK inhibitor study will spur more research into therapeutic interventions for people with precancerous lesions who are at high risk for cancer.

“I’m hoping that this is a direction that multiple researchers might take in the future to really change the dynamics of how we’re going to intervene so that people don’t develop cancer,” he said. “That’s a different mindset than we’ve had previously.”

Eunyoung Choi, PhD, associate professor of Surgery and of Cell and Developmental Biology, is a co-principal investigator of the pyrvinium study along with Katherine Garman, MD, associate professor of Medicine at Duke University. Choi is also a co-author of the study published in Gastroenterology.

Goldenring is supported by grants from the Department of Defense, a Department of Veterans Affairs Merit Review Award, and the National Institutes of Health (R01DK101332 and R01CA272687. Choi is supported by grants from the National Institutes of Health (R37CA244970 and R01CA272687), the Department of Defense, the American Association for Cancer Research, and an American Gastroenterological Association Robert & Sally Funderburg Research Award.

The post Drug shows safety, efficacy for precancerous stomach lesions appeared first on VUMC News.

When 4-year-old Monroe Peterson was diagnosed with cancer, her family was determined to not only rally around her in support but also wanted to make a difference for other patients and families going through a similar experience.

To honor her journey, in November 2024 Monroe’s father, fitness expert and celebrity trainer Gunnar Peterson, started the MVP Challenge on his app, Common Ground, to raise awareness and funds for pediatric cancer efforts at Monroe Carell Jr. Children’s Hospital at Vanderbilt.

The MVP Challenge, named for Monroe Vivian Peterson, included four weeks of guided workouts, question and answer sessions with Gunnar, and an opportunity to win special prizes. The fitness challenge raised funds to support pediatric cancer research, training and care at Monroe Carell.

“For months, Monroe has faced this battle with more grit, determination and positivity than I’ve ever seen,” said Peterson. “She hasn’t backed down; she doesn’t quit; and she moves forward with a smile on her face every day. To honor her strength, we launched the MVP Challenge as a way to come together as a community, push ourselves and raise funds to support children’s cancer treatment and research.”

Monroe was diagnosed with acute myeloid leukemia and completed two rounds of chemotherapy. She received two bone marrow transplants, one from each of her older brothers, and she is now in remission.

During her treatment, Monroe’s family says that she brought positivity, joy and levity to those around her and earned the nickname MVP. Many family members, friends and community members came together in support of the challenge to make it a success.

“We are blown away by the incredible success of the MVP Challenge and know that it would not have been possible without the advocacy, outreach and community engagement work of Gunnar, Jess and the whole Peterson family,” said Debra Friedman, MD, MS, director of the Division of Pediatric Hematology and Oncology at Monroe Carell, deputy director of Vanderbilt-Ingram Cancer Center, and holder of the E. Bronson Ingram Chair in Pediatric Oncology. “This challenge was a wonderful way to honor Monroe’s journey and tenacious spirit.”

Funds raised from the MVP Challenge will support Monroe Carell’s vision to advance personalized pediatric, adolescent and young adult cancer care in the region, specifically leukemia and stem cell research.

The post The real MVP: Fitness challenge raises funds in honor of 4-year-old cancer patient appeared first on VUMC News.

Aimal Khan, MD, assistant professor of Surgery at Vanderbilt University Medical Center, noticed the puzzled or anxious expressions of patients trying to fully comprehend what he was saying during preoperative consultations, so he devised visual aids — three-dimensional models of the lower digestive tract. 

The 3D models allowed patients to easily distinguish the ascending colon from the sigmoid colon, along with other parts of the digestive system. Patients could actually see where the surgery would occur, and Khan noticed that they asked more questions, felt more confident and seemed less anxious.  He devised a study to determine whether his personal observations were scientifically valid. 

The study, which was published June 3 in JAMA Network Open, determined that the 3D models made patients feel they played a bigger role in decision-making and that their anxiety levels decreased. 

The patients were scheduled for partial or complete colon and/or rectal resections for colorectal cancer, diverticulitis or inflammatory disease. Fifty-one patients participated in the study with 28 receiving consultations using the 3D models and 23 receiving conventional consultations. The patients in the 3D arm of the study reported a significantly higher involvement in shared decision-making and significantly reduced anxiety levels compared to the other patients. 

Khan and five other Vanderbilt surgeons conducted the study from March 2022 to June 2023.  

“Using 3D models during consultations allowed our patients to truly visualize their surgery, which not only empowered them to take an active role in decision-making but also significantly eased their anxiety. This approach has the potential to transform how we communicate complex information to our patients. We are currently working with surgeons from other specialties, including thoracic surgery, ENT and surgical oncology, to validate these findings in a multicenter randomized trial,” Khan said. 

The findings are important because other studies have shown that improvements in shared decision-making are associated with reduced hospital stays, lower health care utilization, improvement in patient-reported health outcomes and fewer emergency department visits.  

The 3D models used in the study were developed in collaboration with the Department of Radiology. The modular designs, which were made with 3D printing, allowed each segment of the colon and rectum to be magnetically detached and reattached. 

To the knowledge of the study’s authors, this is the first randomized clinical trial to compare the effectiveness of a 3D-printed model with usual care on colorectal surgery patients’ involvement in decision-making, anxiety and education. 

Other Vanderbilt researchers who authored the study are Danish Ali, MD, Shannon McChesney, MD, Michael Hopkins, MD, Molly Ford, MD, Roberta Muldoon, MD, Timothy Geiger, MD, MMHC, Alexander Hawkins, MD, MPH, Georgina Sellyn, MA, Hillary Samaras, RN, and Dann Martin, MD, MS.

The post Presurgery consults with patients using 3D models improve shared decision-making and reduce anxiety  appeared first on VUMC News.

Cases of appendiceal cancer tripled for Americans born between 1976 to 1984 and quadrupled for those born between 1981 to 1989, according to a study published June 9 in the Annals of Internal Medicine. 

The study compared chronological data in five-year intervals from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program, using 1941 to 1949 as the baseline. The lead author, Andreana Holowatyj, PhD, MSCI, assistant professor of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, said the findings reveal the need for increased awareness about appendiceal cancer from both clinicians and the public as well as more research to determine the reasons for the sharp spike in incidence.  

“When you take these alarming rates that we are seeing for appendiceal cancer across generations, together with the fact that 1 in every 3 patients diagnosed with appendiceal cancer is diagnosed under the age of 50, these point to a timely need for everyone to be aware of the signs and symptoms of appendix cancer.

“Albeit cancer of the appendix is rare, it is important for individuals who have these symptoms to see a health care professional. Ruling out the possibility of an appendix cancer diagnosis, or diagnosing it early, is important for this cancer as we continue to learn what factors may be contributing to this worrisome trend,” Holowatyj said.

Symptoms may include abdominal pain, bloating, changes in bowel habits, and loss of appetite. 

Appendiceal cancer is a rare cancer with about 3,000 new cases diagnosed every year in the United States, according to prior studies, but Holowatyj and colleagues took a closer look at statistics by combing through the SEER database. 

“As incidence rates in younger generations are often indicative of future disease burden, these results support the need for histology-specific investigations of appendiceal adenocarcinoma, as well as increased education and awareness of appendiceal adenocarcinomas among health care providers and the public,” the study stated. 

Appendiceal cancer has had no standardized screening guidelines, risk factors or tumor classifications — a lack of clinical evidence that has resulted in late diagnosis and poor prognosis. Up to 1 of every 2 patients is diagnosed with distant metastatic disease, and five-year survival rates vary between 10% and 63%.  

Earlier this year, Holowatyj and a team of experts identified six key research priority areas to deliver a fundamental understanding of appendiceal tumors and to improve treatments and outcomes for patients.  

The recommendations published Feb. 20 in Nature Reviews Cancer are the result of a concerted focus by the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation to better understand the disease that afflicts an estimated 3,000 new patients across all age groups each year. 

The recommendations arose from the inaugural ACPMP Research Foundation Scientific Think Tank, sponsored by ACPMP and chaired by Holowatyj at Vanderbilt-Ingram Cancer Center in December 2023. 

The current study in the Annals of Internal Medicine received support from ACPMP and the National Institutes of Health (grants K12HD043483 and P50CA236733). 

Other authors on the study are Mary Kay Washington, MD, PhD, professor of Pathology, Microbiology and Immunology at VUMC, Richard Goldberg, MD, of the West Virginia University School of Medicine, and Caitlin Murphy, PhD, MPH, of the UT Health Houston School of Public Health. 

The post Study shows sharp increase in appendix cancer for Generation X and millennials  appeared first on VUMC News.

Researchers at Vanderbilt University Medical Center using artificial intelligence have helped develop two technologies for improving cancer care. 

One technology called MSI-SEER, described in a study published in npj Digital Medicine, better predicts microsatellite instability-high status from standard pathology slides and provides clinicians with specific data, including any uncertainties with predictions. The other technology, a breakthrough three-dimensional imaging tool described in a study published in Nature Communications, has transformative potential beyond cancer diagnostics. 

These new technologies showcase how VUMC researchers are using the power of AI to meet a wide range of medical needs, said Tae Hyun Hwang, PhD, professor of Surgery, founding director of the Molecular AI Initiative, and director of AI Research for the Vanderbilt Section of Surgical Sciences. He noted that the 3D imaging could significantly advance development of therapeutic drugs, provide more detailed assessments of organ transplant rejections, assist with personalized medicine, and aid with tissue analysis for biopharmaceutical development. 

“This technology fundamentally redefines how we visualize and analyze tissue architecture, moving from traditional two-dimensional views to full 3D microenvironment mapping at the subcellular level,” said Hwang, a corresponding author of the study, who provided senior leadership in the development, validation and translational development of the technology. 

The 3D study published in Nature Communications introduced an innovative framework that integrates holotomography with deep learning to generate hematoxylin- and eosin-stained images directly from thick tissue samples. This noninvasive, AI-driven approach preserves tissue integrity, overcomes the traditional 4- to 5-micron thickness limit of routine histology, and enables volumetric visualization of biological structures up to 50 microns thick. 

By preserving tissue samples and avoiding chemical alteration, this method also ensures compatibility with downstream molecular assays, such as spatial transcriptomics, proteomics and genomic profiling — enhancing the breadth and depth of diagnostic and research capabilities.  

“This is not just a digital copy of hematoxylin- and eosin-staining,” Hwang said. “It is a foundational platform for AI-driven volumetric tissue analysis that accelerates discoveries in oncology, immunology, regenerative medicine and therapeutic development.” 

The multi-institutional effort also included researchers from KAIST, Tomocube Inc., Yonsei University College of Medicine and Mayo Clinic. Hwang received funding support from the National Cancer Institute (grants R01CA276690, R37CA265967, U01CA294518). 

VUMC researchers developed the MSI-SEER predictor technology in collaboration with Mayo Clinic, Yonsei Severance Hospital and Seoul St. Mary’s Hospital in South Korea. This technology identifies patients who will benefit from an immunotherapy that might otherwise be missed with existing prediction models. 

Microsatellite instability-high (MSI-H) status is a well-established biomarker used to identify patients likely to respond to immune checkpoint inhibitors, especially patients with gastrointestinal cancers. However, traditional testing methods — including immunohistochemistry and PCR-based assays — offer only a binary result and often miss focal or heterogeneous MSI-H regions within tumors.  

MSI-SEER overcomes this limitation by dividing each pathology slide into thousands of image tiles and generating region-by-region predictions of MSI-H probability. This enables visualization of the tumor’s spatial heterogeneity and quantification of the MSI-H fraction across the tumor. In multiple cases, MSI-SEER identified MSI-H regions in tumors previously classified as microsatellite stability, and those patients subsequently responded to immunotherapy. 

“This is analogous to what we say in HER2-low gastric cancer, where patients previously not eligible for targeted therapy are now being treated with agents like trastuzumab deruxtecan,” Hwang said. “Likewise, patients with low or heterogeneous MSI-features may now be reconsidered for immunotherapy if spatially resolved analysis like MSI-SEER is used.” 

A key innovation of MSI-SEER is its ability to report not only predictions but the confidence level for each result.  

“AI should not dictate clinical decisions; it should support them,” Hwang said. “MSI-SEER gives clinicians both the answer and a measure of how reliable the answer is. It’s not about replacing human expertise but about combining the best of AI computation with physician judgment to drive safe, precise decisions.” 

Hwang, who conceptualized the study and is the paper’s senior author, received research support from the National Cancer Institute and the Department of Defense. He also received support from the Eric and Wendy Schmidt Fund for AI Research and Innovation and the American Association for Cancer Research Innovation and Discovery Grant.  

Other VUMC researchers who authored the study are Sunho Park, PhD, Minji Kim, MS, Jean Clemenceau, PhD, and Inyeop Jang, PhD. 

The post AI researchers develop new technologies for cancer care   appeared first on VUMC News.